Please find attached herewith the Annual Report for the Financial Year 2025-26

Date: August 04, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoi Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS Sub: Submission of Annual Report for the Financial Year 2025-26 and Notice of the Annual General Meeting Dear Sir/Madam, Pursuant to Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable regulations, kindly find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26 along with the Notice convening the 34th Annual General Meeting to be held on Thursday, August 27, 2026 at 11:00 a.m. through electronic mode (video conference or other audio visual means) being sent to the members through electronic mode. Further, the aforesaid Annual Report along with Notice has also been uploaded on the website of the Company at https://www.marksanspharma.com/pdf/marksans-annual- report-2025-26.pdf The Company is providing e-voting facility to its shareholders, in respect of all shareholders resolutions, to be passed at the AGM. The e-voting period will start on Monday, August 24, 2026 at 09:00 A.M. and will end on Wednesday, August 26, 2026 at 05:00 P.M. The facility for voting through e-voting system will also be made available during the AGM. Members attending the AGM through VC / OAVM facility who have not cast their vote by remote e-voting will be able to vote during the AGM. We request you to take the aforesaid on records. Thanking You. For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Encl.: As Above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com Marksans Pharma Limited Annual Report 2025-26 Relentless. Resilient. Rising. Contents Theme introduction Resilient. Relentless. 01-38 126-238 Rising. Company Overview Financial Statements About Us 2 Standalone Journey 4 Independent Auditor’s Report 127 Our mission to advance global well-being has shaped our journey and defines the way we move Geographic Presence 6 Balance Sheet 136 forward. Built on a robust manufacturing base, a diversified product portfolio and a strategic Chairman’s Message 8 Statement of Profit and Loss 137 focus on expanding our presence across regulated markets, we have established a platform for Q&A with the CFO 10 Statement of Changes in Equity 138 Performance Highlights 12 Cash Flow Statement 140 sustainable growth. Our forward integration capabilities, complemented by continuous innovation, Overview of Our Key Market Areas 16 Notes to the Financial Statements 142 reinforce our competitive advantage and enable us to maintain a differentiated product pipeline. Business Model 18 Risk Management 20 These core competencies have enabled us to navigate an evolving pharmaceutical landscape while upholding uncompromising Stakeholder Engagement 22 Consolidated standards of quality, compliance and operational excellence. A robust R&D ecosystem, supported by advanced manufacturing Research and Development 24 Independent Auditor’s Report 183 capabilities, allows us to meet increasingly rigorous regulatory requirements across global markets. Together with our Strategy 26 Balance Sheet 190 presence across regulated and emerging geographies, these capabilities have earned Marksans the trust of customers and ESG 28 Statement of Profit and Loss 191 partners worldwide. Environment 30 Statement of Changes in Equity 192 Social 32 Cash Flow Statement 194 This resilience is matched by a relentless pursuit of progress. As healthcare expectations rise, technologies advance and Governance 34 Notes to the Financial Statements 196 regulatory frameworks evolve, we remain focused on anticipating change rather than responding to it. Through close Awards/Recognition 36 collaboration with partners and regulatory authorities, we continue to develop high-quality products that address changing Board of Directors 37 patient needs and create lasting value. Corporate Information 38 Today, Marksans is rising alongside a nation that is strengthening its position in global healthcare. Our strategy is centred on 239-255 deepening our presence across key markets, broadening our global reach and pursuing opportunities that support sustainable, long-term growth. As we look ahead, we remain committed to delivering accessible healthcare solutions, advancing scientific 39-125 Notice 239 excellence and building a stronger, more resilient future for patients, partners and stakeholders alike. Statutory Reports Management Discussion & Analysis 39 Directors’ Report 50 Corporate Governance Report 64 Business Responsibility & Sustainability Reporting 81 To see the online version of this report please log on to www.marksanspharma.com Forward Looking Statement Some information in this report may contain forward-looking statements. We have based these forward looking statements on our current beliefs, expectations and intentions as to facts, actions and events that will or may occur in the future. Such statements generally are identified by forward-looking words such as “believe,” “plan,” “anticipate,” “continue,” “estimate,” “expect,” “may,” “will” or other similar words. A forward-looking statement may include a statement of the assumptions or basis underlying the forward-looking statement. We have chosen these assumptions or basis in good faith, and we believe that they are reasonable in all material respects. However, we caution you that forward looking statements and assumed facts or bases almost always vary from actual results, and the differences between the results implied by the forward-looking statements and assumed facts or bases and actual results can be material, depending on the circumstances. Corporate Overview Statutory Reports Financial Statements About Us Delivering everyday Key Highlights healthcare solutions ₹ 3,033 cr ₹ 601 cr 20.4% Marksans Pharma is a globally trusted pharmaceutical company, distinguished by our customer-centric approach and strong presence in regulated markets. We develop, manufacture and distribute a wide Revenue EBITDA EBITDA Margin range of over-the-counter (OTC) and prescription (Rx) drugs, aligning our portfolio with the evolving needs of patients and healthcare providers worldwide. Backed by robust R&D capabilities and advanced manufacturing facilities across domestic and international locations, ₹ 420 cr 4 4 we have established a strong presence in the United Kingdom, where we rank among the top five Indian companies and continue to expand our footprint in the United States and other regulated markets. Headquartered in Mumbai, we PAT Manufacturing Units R&D Centres operate in over 60 countries, supported by an integrated business model and a capable workforce, enabling us to pursue sustained growth and long-term value creation. 350+ 2,000+ 2000+ Products SKUs Total Employees Vision Core Values $175 mn in US To become a respected, profitable, and integrated Customer Centric Approach global pharmaceutical company We are committed to delivering drugs that Amongst the top Indian cater to the specific needs of our consumers Companies in OTC segment Commitment to Excellence Our quality-focused approach extends from research and development to manufacturing Amongst Top 5 and customer service Our Strengths Global Responsibility Indian Pharma companies Robust QC and QA processes We are committed to sustainable practices and in UK Adherence to cGMP norms ethical business conduct Continuous improvement across products, Empowering People processes and skills We empower our employees through a culture Alignment with evolving client requirements of collaboration and innovation Accreditations Manufacturing facilities approved by US FDA, [Showing first 8,000 characters — download PDF for full document]